Ionis Pharmaceuticals NASDAQ: IONS remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more slowly than expected, CEO Brett Monia said at the UBS Global Biopharma Conference.
Monia said physicians are still becoming familiar with the medicine, its mechanism and the process for getting patients access. More than 1,500 health care providers had prescribed TRYNGOLZA in the first few months of the launch, but 75% had written a prescription for only one patient, he said.
“Many of the physicians that are the early adopters for TRYNGOLZA want to see that first patient experience,” Monia said. He added that repeat prescribing was growing as doctors gained experience with the drug.
TRYNGOLZA launch and market opportunity
TRYNGOLZA is approved for severe hypertriglyceridemia, a condition involving elevated triglyceride levels that can put patients at risk of acute pancreatitis. It was previously approved for familial chylomicronemia syndrome, a rare genetic form of the condition.
Monia said Ionis’ Phase III trial showed reductions in triglycerides and acute pancreatitis attacks. The drug is administered once a month by patients using an auto-injector, he said.
The CEO estimated that several million people in the U.S. have severe hypertriglyceridemia, including about 1 million whom Ionis considers at high risk. He said the company’s peak sales estimate assumes a competitor with a similar product profile enters the market.
The conference moderator noted that Arrowhead expects its competing drug, REDEMPLO, to be approved for the condition in the second quarter of 2027. Monia said Ionis’ $3 billion-plus estimate assumes two companies can succeed in the market, and that a second competitor could help educate physicians and patients about the disease.
Outside the U.S., Ionis has partnered with Sobi on commercialization. Monia said Sobi has estimated more than $1 billion in peak European sales for severe hypertriglyceridemia. He said the drug had received a positive opinion from Europe’s Committee for Medicinal Products for Human Use, with approval expected by the end of the year or early the following year.
Access and a follow-on treatment
Monia said Ionis lowered TRYNGOLZA’s price when it expanded from a rare-disease indication to the broader severe hypertriglyceridemia population. Payers so far are covering the drug according to its label rather than limiting it to a smaller group of patients at the highest risk, he said.
Ionis is also using a Quick Start program intended to get patients on treatment more quickly while access processes are addressed. Monia said a smooth initial experience can encourage physicians to prescribe the drug to more patients.
Ionis is developing ION775, a follow-on treatment designed primarily to improve dosing convenience. The candidate is in Phase II for severe hypertriglyceridemia and could potentially be administered once or twice a year, compared with TRYNGOLZA’s monthly dosing, Monia said.
Neurology pipeline
Monia also discussed ZANVASTRO, Ionis’ recently launched treatment for the rare neurodegenerative disorder Alexander disease. The company has projected peak U.S. sales of more than $100 million for the drug, which Monia described as Ionis’ first independent neurology launch.
Ionis expects Phase III data in the second half of the following year for obudanersen, its investigational treatment for Angelman syndrome, he said. Asked about disappointing results from a competing program, Monia said Ionis believes its candidate is being tested at an appropriate dose, based in part on its Phase II open-label data.
Monia said researchers have struggled to develop an assay to measure the relevant protein in circulation, but that Ionis has observed changes in EEG patterns that it views as a biomarker. He also said obudanersen had been well tolerated at the targeted dose in testing.
Across its portfolio, Ionis has seven FDA-approved medicines covering eight indications and four Phase III programs in development, Monia said.
About Ionis Pharmaceuticals (NASDAQ:IONS)
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company's research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ionis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.
While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.